Duodart dutasteride/tamsulosin regulatory update

GlaxoSmithKline disclosed in its earnings that on March 20 it submitted an NDA to FDA for Duodart dutasteride/tamsulosin to treat symptomatic benign prostatic hyperplasia (BPH) and reduce the risk of ...